CR Bard Inc. (BCR) Wrap Up:

C. R. Bard, Inc. and its subsidiaries engage in the design, manufacture, packaging, distribution, and sale of medical, surgical, diagnostic, and patient care devices worldwide. It offers vascular, urology, oncology, and surgical specialty products. The company’s vascular products include percutaneous transluminal angioplasty catheters, guidewires, introducers and accessories, peripheral stents, stent grafts, vena cava filters, and biopsy devices; electrophysiology products, such as electrophysiology laboratory systems and diagnostic, therapeutic, and temporary pacing electrode catheters; and fabrics, meshes, and implantable vascular grafts. Its urology products comprise infection control Foley catheters to reduce the rate of urinary tract infections; surgical slings used to treat stress urinary incontinence; natural and synthetic devices to treat pelvic floor and vaginal prolapse; brachytherapy services, devices, and radioactive seeds used to treat prostate cancer; urine monitoring and collection systems; ureteral stents; fecal incontinence products; and specialty devices for ureteroscopic procedures and stone removal. The company offers various devices to treat and manage cancers, and other diseases and disorders, including specialty access catheters, ports, vascular access ultrasound devices, and enteral feeding devices. Its surgical specialty products include patches and fixation systems for hernia and other soft tissue repairs; irrigation devices for orthopaedic, laparoscopic, and gynecological procedures; and products for topical hemostasis. C. R. Bard sells its products directly and through distributors to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. The company was founded in 1907 and is based in Murray Hill, New Jersey.